Not All Intravenous Irons Are Created Equal: Considerations for Rate of Iron Release, Efficacy, Safety, and Tolerability

A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.

Understanding local health care priorities is essential to developing meaningful solutions.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.

A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.

The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.

REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.

Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.